|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2010-9-16
|
|
pubmed:abstractText |
Neuroblastoma (NB) is an aggressive tumor of the developing peripheral nervous system that remains difficult to cure in the advanced stages. The poor prognosis for high-risk NB patients is associated with common disease recurrences that fail to respond to available therapies. NB tumor-initiating cells (TICs), isolated from metastases and primary tumors, may escape treatment and contribute to tumor relapse. New therapies that target the TICs may therefore prevent or treat tumor recurrences.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BlakelyKim MKM,
pubmed-author:CezardTimotheeT,
pubmed-author:GrinshteinNatalieN,
pubmed-author:HansfordLoen MLM,
pubmed-author:HirstMartinM,
pubmed-author:JonesStevenS,
pubmed-author:KaplanDavid RDR,
pubmed-author:KislingerThomasT,
pubmed-author:MarraMarco AMA,
pubmed-author:MaslovaAlexandraA,
pubmed-author:MillerFredaF,
pubmed-author:MoffatJasonJ,
pubmed-author:MooreRichardR,
pubmed-author:MoranMichael FMF,
pubmed-author:MorinRyan DRD,
pubmed-author:MorozovaOlenaO,
pubmed-author:SmithKristen MKM,
pubmed-author:TaylorPaulP,
pubmed-author:ThiessenNinaN,
pubmed-author:VarholRichardR,
pubmed-author:VojvodicMilijanaM,
pubmed-author:ZhaoYongjunY
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4572-82
|
|
pubmed:dateRevised |
2011-7-11
|
|
pubmed:meshHeading |
pubmed-meshheading:20651058-Antineoplastic Agents,
pubmed-meshheading:20651058-Chromatography, Liquid,
pubmed-meshheading:20651058-Drug Evaluation, Preclinical,
pubmed-meshheading:20651058-Gene Expression Profiling,
pubmed-meshheading:20651058-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20651058-Gene Knockdown Techniques,
pubmed-meshheading:20651058-Humans,
pubmed-meshheading:20651058-Microarray Analysis,
pubmed-meshheading:20651058-Molecular Targeted Therapy,
pubmed-meshheading:20651058-Neoplastic Stem Cells,
pubmed-meshheading:20651058-Neuroblastoma,
pubmed-meshheading:20651058-Protein Kinase Inhibitors,
pubmed-meshheading:20651058-Protein-Serine-Threonine Kinases,
pubmed-meshheading:20651058-RNA, Small Interfering,
pubmed-meshheading:20651058-Systems Biology,
pubmed-meshheading:20651058-Tandem Mass Spectrometry,
pubmed-meshheading:20651058-Therapies, Investigational,
pubmed-meshheading:20651058-Validation Studies as Topic
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.
|
|
pubmed:affiliation |
Genome Sciences Centre, BC Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada. omorozova@bcgsc.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
